Loading...
Loading...
ADPT| Name | Value |
|---|---|
| Revenues | 58.9M |
| Cost of Revenue | 18.0M |
| Gross Profit | 40.9M |
| Operating Expense | 65.9M |
| Operating I/L | -25.0M |
| Other Income/Expense | -0.6M |
| Interest Income | 2.4M |
| Pretax | -25.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -25.6M |
Adaptive Biotechnologies Corporation is a commercial-stage company specializing in immune medicine. Its immunoSEQ platform and core immunosequencing product are used for translational research, prognostic and diagnostic signals discovery, and T-Detect COVID for confirming past COVID-19 infection. The company also offers clonoSEQ for minimal residual disease detection and monitoring in patients with certain cancers, and immunoSEQ T-MAP COVID for measuring T-cell immune response to vaccines. Adaptive Biotechnologies serves life sciences research, clinical diagnostics, and drug discovery applications, with strategic collaborations for the development, manufacture, and commercialization of neoantigen directed T cell therapies and diagnostic tests for early disease detection.
